Michael Shetzline - Mar 8, 2024 Form 4 Insider Report for IRONWOOD PHARMACEUTICALS INC (IRWD)

Role
CMO,SVP,Head-Res&Drug
Signature
/s/ Brian Tessler, Attorney-in-Fact
Stock symbol
IRWD
Transactions as of
Mar 8, 2024
Transactions value $
$0
Form type
4
Date filed
3/12/2024, 04:05 PM
Previous filing
Feb 14, 2024
Next filing
May 22, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRWD Class A Common Stock Options Exercise $0 +34.9K +8.85% $0.00 430K Mar 8, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IRWD Performance-based Restricted Stock Unit Options Exercise $0 -34.9K -100% $0.00* 0 Mar 8, 2024 Class A Common Stock 34.9K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares earned upon satisfaction of certain performance criteria associated with performance-based restricted stock units (PSUs) granted on March 8, 2023. The earned PSUs were certified on February 12, 2024, and March 7, 2024, and vested on March 8, 2024.
F2 Each PSU represents a contingent right to receive shares of the Issuer's Class A Common Stock upon vesting such award. The PSUs are earned upon the Issuer's Class A Common Stock achieving a specified price per share.
F3 Additional PSUs may vest upon the Issuer's Class A Common Stock achieving specified prices per share beyond the previously achieved vesting targets.